Cowen Maintains Buy on Evolent Health (EVH) March 2026, PT Cut to $7

On March 02, 2026 at 09:37 AM the EVH analyst rating from Cowen & Co. stayed at Buy while the firm lowered its price target to $7. Cowen’s note kept optimism on the shares but trimmed near-term forecasts, citing 2026 outlook changes. This change was reported by StreetInsider and followed comments in the company’s recent earnings call. Investors should note the mix of continued conviction and a weaker near-term projection for Evolent Health, Inc.